In terms of prostate cancer fusion genes, the expression of ERG has been shown to be retained in the PDXs along with other molecular, histopathologic, and genomic characteristics (Palanisamy et al., 2020), indicating PDXs to be a valuable strategy to assess fusion-specific therapeutic options in the future. Here, ERG is linked to prostate cancer.